Botensilimab, Balstilimab, and SBRT in Colorectal Cancer

This is a single-arm pilot feasibility study evaluating the combination of Botensilimab and Balstilimab with Radiation Therapy (RT) in Non-Microsatellite Instability High (MSI-H) or Proficient Mismatch Repair (pMMR) chemorefractory colorectal cancer (CRC) with liver metastasis.

Trial Details

NCT ID
NCT07128355
Phase
EARLY_PHASE1
Sponsor
Massachusetts General Hospital
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Stereotactic Body Radiation Therapy (SBRT)
  • Botensilimab
  • Balstilimab
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Participants must have histologically or cytologically confirmed adenocarcinoma of colorectal origin.
  • MSS or pMMR status confirmed by IHC or PCR.
  • Must have at least 1 measurable (≥ 1 cm) previously unirradiated hepatic lesion amenable to ablative RT and meeting dose constraints. A maximum of …
  • Must have received or confirmed intolerance to 5-FU, Oxaliplatin, and Irinotecan (in any combination).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →